Skip to main content
. Author manuscript; available in PMC: 2018 Apr 15.
Published in final edited form as: Cancer Res. 2017 Feb 16;77(8):2102–2111. doi: 10.1158/0008-5472.CAN-16-2548

Table 1.

Correlation of SLC22A4 expression with survival in AML.

Model* P value HR lower 95% CI upper 95% CI
Overall survival
1 0.0077 0.5939 0.4048 0.8712
2 0.0033 0.5540 0.3738 0.8212
3 0.0074 0.5611 0.3677 0.8562
Event-free survival
1 0.0184 0.6645 0.4731 0.9333
2 <0.0001 0.2089 0.1000 0.4368
3 0.0240 0.6694 0.4724 0.9484
*

Model 1 is only stratified by treatment arms; Model 2 is adjusted by risk and stratified by treatment arms; Model 3 is adjusted by age, MRD, FLT3-ITD, CBF, M7 without t(1;22) and other 11q23, which are the factors that were found to be statistically significant in the original association analyses (18, 19), and stratified by treatment arm. Note that independent of the model, SLC22A4 expression is significantly associated with both overall survival and event free survival outcomes, with higher expression levels being associated with better survival outcomes (ie, hazard ratios significantly less than 1).

Abbreviation: HR, hazard ratio; CI, confidence interval.